BSE filing, NSE: AUROPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Aurobindo Pharma Ltd: key numbers
- Share price
- ₹1,644.80
- Market cap
- ₹95,530 Cr
- Revenue (annual)
- ₹33,653 Cr
- Net profit (annual)
- ₹3,505 Cr
- P/E (TTM)
- 24.2×Sector 46.1×
- Promoter holding
- 51.88%+0.00% QoQ
- FII holding
- 17.41%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aurobindo Pharma Ltd
All →Aurobindo Pharma Other Announcement
Aurobindo Pharma Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as mandated by SEBI regulations.
Aurobindo Pharma Business Update
Aurobindo Pharma received USFDA final approval for Perampanel Tablets in multiple strengths. The product will be manufactured by its subsidiary and launched in Q3FY27.
Aurobindo Pharma Acquisition
Aurobindo Pharma's subsidiary, Apitoria Pharma, has completed the acquisition of the Contract Research Services business of A1 Biochem Group. The deal integrates CRO capabilities into Apitoria's operations.
Aurobindo Pharma Acquisition Worth ₹146.4 Cr
Aurobindo Pharma's subsidiary acquired 100% ownership of US-based A1 Biochem Labs LLC for USD 15.247 million in an all-cash deal.
- Value
- ₹146.4 Cr
Aurobindo Pharma Merger & Restructuring Worth ₹33.8 Cr
Aurobindo Pharma's subsidiary, Apitoria Pharma, completed a 20% stake dilution in A1 Biochem Labs. Dr. Rajendra Gadikota subscribed to securities worth ₹33.80 Crore.
- Value
- ₹33.80 Cr
Aurobindo Pharma Product Launch
Acrotech Biopharma launched ADQUEY (difamilast 1% ointment) in the U.S. and established a dedicated dermatology business unit to support this market entry.
Other board meeting date announcements
All →RateGain Travel Technologies Board Meeting Date
RateGain Travel Technologies will hold a board meeting on 5 November 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. The trading window closes from 1 October 2026 until 48 hours after results.
Tapi Fruit Processing Board Meeting Date
Tapi Fruit Processing will hold a board meeting on November 3, 2026 to consider unaudited standalone and consolidated half-yearly results for September 2026. Trading window closes from October 1 to November 5, 2026.
Parag Milk Foods Board Meeting Date
Parag Milk Foods has notified BSE of a board meeting on 3 November 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended 30 September 2026. Trading window closure runs from 1 October to 5 November 2026.
Vedant Fashions Board Meeting Date
Vedant Fashions will hold a board meeting on 5 November 2026 to consider unaudited results for the quarter and half-year ended September 2026. The meeting is a prior intimation, so no results are approved yet.
Dangee Dums Board Meeting Date
Dangee Dums will hold a board meeting on 2 November 2026 to consider unaudited standalone results for the quarter and half year ended 30 September 2026. Trading window closure runs until 4 November 2026.
Relic Technologies Board Meeting Date
Relic Technologies intimated a board meeting on 2 Nov 2026 to consider unaudited standalone and consolidated Q2 results for the period ended 30 Sep 2026. The trading window closes from 1 Oct 2026 until 48 hours after the results are disseminated.